看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
( ?9 r8 K; P8 i/ l3 K% {, ?2 h, \' Z( ~5 N' J A# V
" ]) R+ ]- o \7 j+ `8 \# zCurrently available feasibility data for possible combination strategies. 6 N& q3 C8 a8 q4 |, @
————————————————————————————————
% c8 o9 ]% D5 D1 o( H* g9 b4 q2 qCombination Feasibility according to preliminary data * ^- N A/ A/ n/ }
——————————————————————————————————
3 y% P4 ]* F5 g' b" c- T; [Bevacizumab + sorafenib Yes, reduced dose
- j& p. R" v2 c- J( cBevacizumab + sunitinib† No 3 m, Q) n' h$ J; D+ S0 _
Bevacizumab + temsirolimus Yes : K8 W3 q) z$ H6 E5 }- `
Bevacizumab + everolimus Yes ) ^, Q6 ?4 k! N& n* u
Sorafenib + sunitinib ? 4 f- N4 p. n* \8 P: p
Sorafenib + temsirolimus Yes, reduced dose
! [; s# N; ^% \3 A: [Sorafenib + everolimus Yes, reduced dose
+ m/ F+ p7 W. V* {/ ]# X- KSunitinib + temsirolimus† No
- h1 l) H! a7 D* [Sunitinib + everolimus ? + n0 e0 D. M9 T, t' V4 Z8 R9 i
Temsirolimus + everolimus ?
5 x- }3 L, E/ E( I/ g# H2 _* ]————————————————————
5 b+ x8 \+ n; v$ {) ]" i: g†Led to US FDA warning.
9 l& c1 S, ?% D: A0 L# v+ ]2 d?: As yet unattempted combination.! O- O- x8 T6 s+ E2 _% \# C
|